SHANGHAI, December 11, 2024/PRNewswire/ -- On December 11, 2024, Dizhe Pharmaceutical's Science and Technology Innovation Board targeted distribution plan was reviewed and approved by the Shanghai Stock Exchange. This is the first time that the refinancing of an unprofitable enterprise on the Shanghai Stock Exchange has been approved since the Securities Regulatory Commission's “Eight Measures on Deepening the Reform of the Science and Technology Innovation Board and the Development of New Quality Productivity” was released.

On November 28, the National Health Insurance Administration held a press conference to introduce the results of the 2024 national basic medical insurance, industrial injury insurance, and maternity insurance drug catalogue adjustments. Two innovative products of Dizhe Pharmaceuticals are included in the new version of the national health insurance catalogue, sulvoritinib tablets (trade name: suvoritinib) and golisitinib capsules (generic name: gaurizhe).

In less than a month, the two major products were successfully included in medical insurance, and the fixed increase plan was successfully reviewed and approved. For Dizhe Pharmaceutical, it can be described as a “double joy”. Medical insurance admission will have a significant acceleration and amplification effect on the commercialization pace of Dizhe Pharmaceutical. The sum of the peak sales of the two drugs in the domestic market is expected to exceed 4 billion yuan.

Digel Pharmaceuticals is positioned for global innovation. Currently, there are 6 new drugs under development at the international multi-center clinical stage. They have a competitive advantage in global differentiation. Continued investment in R&D will accelerate the implementation of innovative results. The refinancing was successfully approved by the Shanghai Stock Exchange. It is estimated that 1.85 billion yuan of capital will be raised, mainly for the company's core product research and development and production base construction, which will provide sufficient “ammunition” for the company's next development. After successful refinancing, Dizhe Pharmaceutical will gain strength. While focusing on deepening innovation at the source, it will accelerate the marketization process of new products and help the company move forward steadily on the fast track of high-quality development.

In recent years, companies listed on the Science and Technology Innovation Board have continued to increase R&D investment. The R&D investment amount in 2023 was 156.1 billion yuan, and the R&D investment in the first three quarters of 2024 was 103.9 billion yuan, all more than double the net profit returned to mother during the same period. Dizhe Pharmaceutical has always been committed to the research and development of innovative drugs at the source. It has invested more than 3.6 billion yuan in R&D and has obtained more than 150 patents. Two innovative products, suvoritinib tablets and golixitinib capsules, were successively approved for marketing within a year, and entered the medical insurance catalogue in the first medical insurance negotiation year after marketing. At the same time, suvortinib tablets were also submitted to the US FDA for marketing in November of this year. As the first targeted drug for Chinese Yuanchuang lung cancer to be submitted for marketing in the US, it has taken an important step in the “global innovation” of Dizhe Pharmaceutical and is another landmark step in the development of innovative drugs in China.

In July of this year, the Executive Meeting of the State Council reviewed and approved the “Full Chain Implementation Plan to Support the Development of Innovative Drugs” to support the “full chain” covering the innovative drug industry. From early investment and financing, R&D, and drug review and approval, to pricing, use, and hospitalization of drugs after marketing, to commercial insurance and medical insurance payments at the final payment end, it opens up all links in the innovation chain industry. In November, the National Health Insurance Administration stepped up its support for “true innovation”. Dizhe Pharmaceuticals' suvoritinib tablets were named at the medical insurance press conference as the first EGFR 20 exon insertion mutation (exon20ins) non-small cell lung cancer (NSCLC) product included in medical insurance. Currently, this product is the only drug approved for the secondary/post-line treatment of EGFR exon20ins NSCLC in China and reimbursed by medical insurance; in December, the Shanghai Stock Exchange increased its support for the innovative drug industry, and Dizhe Pharmaceutical's refinancing plan was successfully reviewed and approved by the Shanghai Stock Exchange, demonstrating the strong support of the capital market to encourage the development of new quality productivity.

With strong support and encouragement from national policies, leaders in the field of local pharmaceutical innovation, such as Dizhe Pharmaceutical, are speeding up their growth with unprecedented speed and determination, and will drive the vigorous development of the entire industry. I believe that in the near future, Dizhe Pharmaceutical will promote more high-quality innovative products to the global market, and gradually grow into a leading enterprise comparable to international pharmaceutical giants in the construction of a globally differentiated competitive advantage.

About Dizhe Pharmaceuticals

Dizhe Pharmaceutical (stock code: 688192.SH) is an innovative biomedical enterprise focusing on the research, development and commercialization of innovative therapies in the fields of malignant tumors and immune diseases. The company adheres to the innovative R&D concept, with the goal of introducing first-in-class drugs (first-in-class) and treatments with breakthrough potential to fill unmet global clinical needs. Based on the industry-leading translational science and new drug molecular design and screening technology platform, the company has established six globally competitive product pipelines. Two of the leading products in critical global clinical trials have all been approved for listing in China. For more information, follow the official WeChat account: Dizal, or visit.